BioNTech, US agency enter into settlement agreement over COVID vaccine royalties
ReutersDec 27, 2024 12:33 PM
Dec 27 (Reuters) - BioNTech 22UAy.DE said on Friday that it had entered into a settlement agreement with the U.S. National Institutes of Health over the payment of royalties and other amounts related to its COVID-19 vaccine.
The German company said it would pay $791.5 million to the U.S. agency as part of the settlement.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D'Silva)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Investing in Robotics Stocks
TradingKey - Robotics has graduated from being a specialized technical innovation to one of the most powerful enablers of productivity in today's economy. Robots are no longer restricted to auto plants and lab coats and now operate across sectors, healthcare and agriculture as well as logistics...TradingKey
2 hours ago
Caterpillar Q2 Earnings Analysis: Revenue Beats Expectations, Diversified Strategy Mitigates Tariff Challenges
Caterpillar’s 2025 Q2 revenue slightly exceeded market expectations at $16.57 billion, but declined 0.8% year-over-year. Weak demand in the Construction and Resources segments partially offset growth in other segments.TradingKey
3 hours ago
AMD Q2 FY2025 Earnings Review: Impressive Growth Stumbles on Export Control Hurdles
TradingKey - Advanced Micro Devices, Inc. (NASDAQ: AMD) released its Q2 FY2025 earnings on August 5, 2025, after market close, delivering robust results driven by record sales in its Data Center and Client segments. Despite a 32% YoY revenue increase, surpassing expectations, the stock dipped aroundTradingKey
6 hours ago
